预约演示
更新于：2024-12-31
Methocarbamol
美索巴莫
更新于：2024-12-31
概要
基本信息
简介以 Robaxin 等品牌名称销售的美索巴莫是一种用于治疗短期肌肉骨骼疼痛的药物。 它可以与休息、物理治疗和止痛药一起使用。 它不太适合用于腰痛。 它对类风湿性关节炎和脑瘫的使用有限。 效果通常在半小时内开始。 口服或静脉注射。 常见的副作用包括头痛、嗜睡和头晕。 严重的副作用可能包括过敏反应、肝脏问题、精神错乱和癫痫发作。 不建议在怀孕和哺乳期间使用。 由于存在受伤风险，老年患者通常应避免使用骨骼肌松弛剂。 美索巴莫是一种中枢性肌肉松弛剂。 它是如何工作的还不清楚，但它似乎不会直接影响肌肉。 |
药物类型 小分子化药 |
别名 (RS)-2-hydroxy-3-(2-methoxyphenoxy)propyl carbamate、Methocarbamol (JAN/USP/INN)、Methocarbamol for Suspension + [11] |
靶点 |
作用机制 CA1抑制剂(碳酸酐酶I抑制剂) |
在研适应症 |
非在研适应症- |
非在研机构- |
最高研发阶段批准上市 |
首次获批日期 美国 (1957-07-16), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C11H15NO5 |
InChIKeyGNXFOGHNGIVQEH-UHFFFAOYSA-N |
CAS号532-03-6 |
关联
16
项与 美索巴莫 相关的临床试验CTR20242833
评估受试制剂美索巴莫片（规格：500 mg）与参比制剂美索巴莫片（规格：500 mg）在健康成年受试者餐后状态下的单中心、开放、随机、单剂量、两周期、两序列、交叉生物等效性研究
CTR20242834
评估受试制剂美索巴莫片（规格：500 mg）与参比制剂美索巴莫片（规格：500 mg）在健康成年受试者空腹状态下的单中心、开放、随机、单剂量、两周期、两序列、交叉生物等效性研究
EUCTR2022-000788-30-PL
Evaluation of the effectiveness of Methocarbamol in the treatment ofspasticity in people with spinal cord injury.
100 项与 美索巴莫 相关的临床结果
登录后查看更多信息
100 项与 美索巴莫 相关的转化医学
登录后查看更多信息
100 项与 美索巴莫 相关的专利（医药）
登录后查看更多信息
287
项与 美索巴莫 相关的文献（医药）2025-01-01ALIMENTARY PHARMACOLOGY & THERAPEUTICS
Management of Muscle Cramps in Patients With Cirrhosis: A Systematic Review of Randomised Controlled Trials
Review
作者: Testro, Adam ; Majumdar, Avik ; Sinclair, Marie ; Abdelmalak, Jonathan ; Makar, Joseph ; Roberts, Andrew T.
ABSTRACT:
Background:
Muscle cramps are common in patients with cirrhosis. Despite their prevalence and impact on health‐related quality of life, there are no widely used clinical practice guidelines for management of muscle cramps in cirrhosis. The aim of this review was to critically evaluate current evidence regarding treatment of muscle cramps in cirrhosis.
Methods:
A systematic review using PubMed, MEDLINE (Ovid), Embase, and Scopus databases was performed on 30 June by two independent reviewers to identify randomised controlled trials (RCTs) reporting interventions for muscle cramps in cirrhotic patients.
Results:
Twelve RCTs evaluating 13 distinct interventions were identified. Baclofen, methocarbamol, orphenadrine, and taurine supplementation reduced cramp frequency, severity, and duration when compared to placebo. Human albumin, pregabalin, and quinidine reduced cramp frequency compared to placebo. Pickle juice reduced cramp severity compared to placebo. BCAA supplementation and calcium carbonate were found to reduce cramp frequency compared to baseline. Stretching demonstrated a signal towards reducing cramp severity and frequency, and meditation had a signal towards reducing severity only when compared to baseline. Electro‐acupuncture was the only intervention which demonstrated no therapeutic effect. Pregabalin was the only agent associated with significant side effects that limited its use.
Conclusion:
Methocarbamol, orphenadrine, and taurine supplementation were found in placebo‐controlled RCTs to be effective in reducing cramp frequency, severity, and duration in cirrhotic patients. All other interventions reported aside from electro‐acupuncture demonstrated a positive impact on cramps. High‐quality RCTs are needed to further investigate the use of these treatments in terms of comparative efficacy and safety.
2024-09-01EMERGENCY MEDICINE JOURNAL
Correspondence on 'Methocarbamol versus diazepam in acute low back pain in the emergency department: a randomised double-blind clinical trial' by Sharifiet al
Letter
作者: Oswald, Jessica C ; Kelly, Timothy D ; Lee, Jon B
2024-07-01Clinical pharmacology and therapeutics
Comparative Risk of Injury with Concurrent Use of Opioids and Skeletal Muscle Relaxants
Article
作者: Horn, John R. ; Leonard, Charles E. ; Chung, Sophie P. ; Hennessy, Sean ; Bilker, Warren B. ; Dublin, Sascha ; Brensinger, Colleen M. ; Chen, Cheng ; Tiwari, Anika ; Miano, Todd A.
Concurrent use of skeletal muscle relaxants (SMRs) and opioids has been linked to an increased risk of injury. However, it remains unclear whether the injury risks differ by specific SMR when combined with opioids. We conducted nine retrospective cohort studies within a US Medicaid population. Each cohort consisted exclusively of person‐time exposed to both an SMR and one of the three most dispensed opioids—hydrocodone, oxycodone, and tramadol. Opioid users were further divided into three cohorts based on the initiation order of SMRs and opioids—synchronically triggered, opioid‐triggered, and SMR‐triggered. Within each cohort, we used Cox proportional hazard models to compare the injury rates for different SMRs compared to methocarbamol, adjusting for covariates. We identified 349,543, 139,458, and 218,967 concurrent users of SMRs with hydrocodone, oxycodone, and tramadol, respectively. In the oxycodone‐SMR‐triggered cohort, the adjusted hazard ratios (HRs) were 1.86 (95% CI, 1.23–2.82) for carisoprodol and 1.73 (1.09–2.73) for tizanidine. In the tramadol‐synchronically triggered cohort, the adjusted HRs were 0.69 (0.49–0.97) for metaxalone and 0.62 (0.42–0.90) for tizanidine. In the tramadol‐SMR‐triggered cohort, the adjusted HRs were 1.51 (1.01–2.26) for baclofen and 1.48 (1.03–2.11) for cyclobenzaprine. All other HRs were statistically nonsignificant. In conclusion, the relative injury rate associated with different SMRs used concurrently with the three most dispensed opioids appears to vary depending on the specific opioid and the order of combination initiation. If confirmed by future studies, clinicians should consider the varying injury rates when prescribing SMRs to individuals using hydrocodone, oxycodone, and tramadol.
100 项与 美索巴莫 相关的药物交易
登录后查看更多信息
研发状态
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 肌肉骨骼疼痛 | 美国 | 1957-07-16 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | - | 願廠網窪築觸窪構選簾(艱襯觸夢顧廠繭醖廠顧): RR = 1.32 (95% CI, 1.19 ~ 1.44) 更多 | - | 2023-02-01 | |||
临床4期 | 153 | (Placebo Infusion) | 鏇鬱艱鬱簾艱鑰鹹繭蓋(觸積襯壓鬱鏇積構鹽窪) = 網繭遞鹹築壓壓襯餘糧 淵選網憲鹹選範顧顧膚 (獵窪窪鏇鑰範膚鏇襯淵, 醖築顧壓鹽製顧積窪衊 ~ 觸鹹鹽繭衊願衊鏇齋鏇) 更多 | - | 2020-02-05 | ||
(Ketamine Infusion) | 鏇鬱艱鬱簾艱鑰鹹繭蓋(觸積襯壓鬱鏇積構鹽窪) = 憲窪艱顧襯鹽鹹廠餘蓋 淵選網憲鹹選範顧顧膚 (獵窪窪鏇鑰範膚鏇襯淵, 齋簾鏇餘獵廠鑰遞獵獵 ~ 構願鹹衊網網選積網窪) 更多 | ||||||
临床3期 | 80 | 製簾艱選繭餘選憲顧築(夢鏇獵網醖範膚衊衊餘) = 願構積鏇選鏇壓艱範鏇 構淵顧鹽壓遞製製顧顧 (遞獵衊襯鏇願襯簾齋艱, 鏇網糧簾鹽壓壓範壓獵 ~ 構築廠遞淵顧壓壓壓築) 更多 | - | 2018-07-20 | |||
临床4期 | 240 | Placebo+Naproxen (Placebo) | 製繭憲選糧鬱醖糧鏇觸(遞簾繭齋獵鹽衊網顧範) = 遞糧顧醖鹹觸鹽淵餘廠 築製窪顧鬱醖遞鏇壓鑰 (襯夢夢鏇遞淵廠願願築, 鹽憲鬱鬱襯築壓獵廠鑰 ~ 構遞鹹鏇觸鑰鬱願壓艱) 更多 | - | 2018-06-26 | ||
(Orphenadrine) | 製繭憲選糧鬱醖糧鏇觸(遞簾繭齋獵鹽衊網顧範) = 襯艱製鹽夢鏇糧蓋觸網 築製窪顧鬱醖遞鏇壓鑰 (襯夢夢鏇遞淵廠願願築, 衊鏇窪選顧願窪繭範壓 ~ 窪窪鹹網餘網艱醖衊觸) 更多 | ||||||
临床4期 | 240 | Naproxen+Placebo | 鏇繭範廠齋簾齋觸醖艱(蓋餘範艱構壓顧繭網膚) = 膚獵蓋鬱膚餘簾夢鏇繭 鏇衊鹹糧構夢遞顧選衊 (繭願壓鏇蓋廠繭艱構繭, 8.9 ~ 12.9) | 不佳 | 2018-03-01 | ||
鏇繭範廠齋簾齋觸醖艱(蓋餘範艱構壓顧繭網膚) = 製衊壓壓鑰鑰蓋餘憲顧 鏇衊鹹糧構夢遞顧選衊 (繭願壓鏇蓋廠繭艱構繭, 7.4 ~ 11.5) |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用